The GRIPAP1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population, offering a genetically disrupted GRIPAP1 locus in the A-549 human lung adenocarcinoma cellular background. This polyclonal population, generated by CRISPR/Cas9-mediated gene disruption, provides a heterogeneous loss-of-function model for studying GRIPAP1-dependent processes without selection for a single clonal genotype. The product enables robust functional interrogation of GRIPAP1 in endosomal receptor trafficking and its implications in cancer cell biology.
The parental A-549 cell line, established in 1972 from a 58-year-old Caucasian male with lung adenocarcinoma, serves as a widely utilized in vitro model of Type II alveolar epithelium and lung adenocarcinoma. These adherent epithelial cells retain key features of malignant lung tissue, including tumorigenic potential and characteristic signaling pathways, making them a suitable platform for investigating oncogenic mechanisms. Their ease of culture and amenability to genetic manipulation facilitate detailed molecular and cellular studies.
GRIPAP1 encodes GRIP1-associated protein 1 (GRASP-1), a scaffold protein that orchestrates endosomal trafficking and recycling of AMPA-type glutamate receptors. Mechanistically, GRIPAP1 acts as an adaptor linking GRIP1 to endosomal compartments, facilitating Rab4-dependent recycling of internalized AMPA receptor subunits (GRIA1 and GRIA2) back to the cell surface. It operates within a multiprotein network involving PICK1, the early endosome antigen EEA1, and the actin cytoskeleton (F-actin), dynamically regulating receptor homeostasis and synaptic strength. Disruption of GRIPAP1 expression therefore perturbs this recycling axis, altering surface receptor availability and downstream glutamatergic signaling.
In the A-549 cell line, GRIPAP1’s role extends beyond neuronal receptor trafficking, as emerging evidence implicates endosomal recycling pathways in cancer cell proliferation, migration, and invasion. The knockout of GRIPAP1 in A-549 cells provides a unique model to dissect how scaffold-mediated receptor sorting influences lung adenocarcinoma cell behavior. By uncoupling GRIPAP1 from its interactors such as GRIP1 and Rab4, researchers can delineate the contribution of endosomal trafficking to tumor-related phenotypes, including actin cytoskeleton remodeling and surface receptor-mediated signaling.
These polyclonal knockout cells are ideally suited for a range of experimental applications, including co-immunoprecipitation to map protein interaction networks, immunofluorescence microscopy to visualize endosomal dynamics, and surface biotinylation/recycling assays to quantify AMPA receptor trafficking. Additionally, they support functional studies in cancer cell biology, such as cell migration, invasion, and proliferation assays, and can be employed in drug screening campaigns to identify modulators of receptor recycling. For further technical details or ordering information, please contact Ascent Research.
